PROBLEM TO BE SOLVED: To provide compositions for treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1, Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.SOLUTION: A composition comprises an RNAi agent comprising a first strand and a second strand. The first strand comprises a specific sequence. The lengths of the first and second strands are each at most 30 nucleotides. The first and/or second strand is modified or unmodified.SELECTED DRAWING: None
